Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.

Mader, Orla; Juillerat, Pascal; Biedermann, Luc; Michetti, Pierre; Hruz, Petr; Pittet, Valerie; Rogler, Gerhard; Zahnd-Straumann, Nadine; Seibold, Frank (2021). Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements. United european gastroenterology journal, 9(3), pp. 398-406. Sage 10.1177/2050640620965106

[img] Text
2050640620965106.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (741kB) | Request a copy


Vedolizumab (VDZ), a humanized monoclonal antibody against α4β7-integrin, has shown efficacy in inflammatory bowel disease (IBD). It is of importance to assess the mid- to long-term efficacy of VDZ using real-life data.


Our study aimed to determine the efficacy of VDZ in patients with IBD with and without prior exposure to anti-tumour necrosis factor (TNF) treatments in a real-life setting. Furthermore, we investigated confounding factors influencing the remission to VDZ.


Patients participating in the Swiss IBD Cohort Study were included in this study. Remission was defined as calprotectin <200 mg/kg stool and/or mucosal healing determined by endoscopy. End points were determined between months 4 and 8 (T1) and between months 12 and 16 (T2) after VDZ induction.


Remission was reported in 50.5% (110/218) of patients in T1 (48.7% Crohn's disease (CD) and 52.5% ulcerative colitis (UC)) and 46.8% (102/218) in T2 (47% CD and 46.5% UC). In UC patients, a significantly higher remission rate was achieved in T2 among anti-TNF-naive patients (57.7%) compared to anti-TNF-experienced patients (34.7%; p = 0.02; odds ratio=0.39, 95% confidence interval 0.17-0.87). In patients with CD, no difference could be seen in either evaluation intervals. Multivariable analysis showed that disease duration significantly influenced remission rates among UC patients. A late response to VDZ therapy with an achievement of remission in T2 was seen in a fifth of all patients (CD 21.7%, UC 20.8%). VDZ treatment was stopped in a third of all patients (31.8%) due to non-response, adverse events or aggravation of extra-intestinal manifestations.


In a real-life national cohort setting, VDZ induced remission in more than half of IBD patients. Previous treatment with anti-TNF agents was associated with a significant lower efficacy of VDZ in UC but not in CD patients.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology

UniBE Contributor:

Juillerat, Pascal


600 Technology > 610 Medicine & health








Rahel Fuhrer

Date Deposited:

18 Dec 2020 16:30

Last Modified:

05 May 2021 01:32

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

Crohn’s disease Vedolizumab adverse events anti-TNF experienced anti-TNF naive inflammatory bowel disease real-life data remission safety ulcerative colitis





Actions (login required)

Edit item Edit item
Provide Feedback